Loading…
Denali Therapeutics Inc. is projected to rise to $30.99 by 2027, a +21% move from its current price of $25.68. DNLI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $25.08 | $25.69 | $26.32 | +0.04% |
| Jul 13 | $24.84 | $25.70 | $26.59 | +0.08% |
| Jul 14 | $24.66 | $25.71 | $26.80 | +0.12% |
| Jul 15 | $24.51 | $25.72 | $26.99 | +0.16% |
| Jul 16 | $24.38 | $25.73 | $27.15 | +0.20% |
| Jul 17 | $24.27 | $25.74 | $27.30 | +0.24% |
| Jul 18 | $24.17 | $25.75 | $27.44 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.17 | $25.75 | $27.44 | +0.28% |
| Week 2 | $23.60 | $25.82 | $28.26 | +0.56% |
| Week 3 | $23.20 | $25.90 | $28.91 | +0.85% |
| Week 4 | $22.87 | $25.97 | $29.49 | +1.13% |
| Week 5 | $22.59 | $26.04 | $30.02 | +1.41% |
| Week 6 | $22.35 | $26.12 | $30.52 | +1.70% |
| Week 7 | $22.13 | $26.19 | $30.99 | +1.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Denali Therapeutics Inc. is a biopharmaceutical company that discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company pursues a broad portfolio, including Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 for frontotemporal dementia-granulin; DNL126 for MPS IIIA; and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Its Enzyme Transport Vehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease.
The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. The description places the company in the Healthcare sector.
DNLI is currently priced at $25.57, with a market cap of $4.06B and a market rank of 1537.
The 30-day forecast landscape shows room for upside beyond the current price, with a 2026 baseline min of $16.02, an avg of $25.57, and a max of $34.97 (sentiment: NEUTRAL). The 2030 outlook features an average price of $58.82 and an ROI of 130, with a bullish tone. By 2040 the average is $143.20 (ROI 460) and by 2050 the average reaches $342.77 (ROI 1240.5), both with bullish sentiment.
A major floor 36.8% below — a decisive break under it would weaken the trend.
The nearest floor, 24.6% below — buyers have tended to step in here.
The nearest ceiling, 6.0% above — a clean break opens room to run.
A major ceiling 24.4% above — clearing it would confirm fresh momentum.
Key DNLI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DNLI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $26.33 | Sell | $26.23 | Sell |
| MA 10 | $26.06 | Sell | $25.82 | Sell |
| MA 20 | $24.63 | Buy | $24.69 | Buy |
| MA 50 | $21.55 | Buy | $22.63 | Buy |
| MA 100 | $20.91 | Buy | $21.21 | Buy |
| MA 200 | $19.17 | Buy | $19.85 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.27 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 47.45 | Neutral |
| Williams %R (14) | -48.42 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 3.67 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 51.58 | Neutral |
| TRIX (15) | 1.00 | Buy |
| Awesome (5,34) | 3.62 | Buy |
| Ultimate (7,14,28) | 57.21 | Neutral |
| Momentum (10) | 0.95 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 26.75 | Sell |
| ADX (14) | 36.19 | Buy |
| ATR (14) | 0.52 | Info |
The near-term technical picture is bullish. RSI14 sits around 70, and the price is trading above the SMA50 of $20.40 and the SMA200 of $18.56, suggesting positive momentum relative to short- and medium-term trends.
Support is noted at $18.11 and resistance at $24.82, framing a near-term path that could challenge the $24.82 level. The 30-day price range runs from a low of $21.53 to a high of $30.37, indicating active price exploration within that window. Annualized volatility is about 50%, signaling meaningful price fluctuation potential in the month ahead.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.02 | $25.68 | $34.30 | 0% | Neutral | |
| $24.94 | $30.99 | $40.56 | +21% | Bullish | |
| $30.49 | $38.80 | $52.50 | +51% | Bullish | |
| $36.62 | $47.55 | $66.03 | +85% | Bullish | |
| $42.95 | $56.77 | $80.57 | +121% | Bullish | |
| $46.19 | $62.04 | $89.75 | +142% | Bullish | |
| $46.85 | $63.87 | $94.00 | +149% | Bullish | |
| $53.77 | $74.33 | $111.13 | +189% | Bullish | |
| $57.72 | $80.85 | $122.63 | +215% | Bullish | |
| $65.38 | $92.75 | $142.57 | +261% | Bullish | |
| $90.59 | $136.02 | $221.19 | +430% | Bullish | |
| $190.81 | $315.50 | $557.23 | +11.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.02 | $25.68 | $30.73 | +0.00% |
| August 2026 | $21.92 | $25.80 | $31.11 | +0.45% |
| September 2026 | $22.50 | $26.64 | $32.44 | +3.26% |
| October 2026 | $23.29 | $27.71 | $34.04 | +4.05% |
| November 2026 | $23.14 | $27.66 | $34.20 | -0.20% |
| December 2026 | $22.96 | $27.56 | $34.30 | -0.36% |
Click any year to see its month-by-month DNLI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DNLI to range from $16.02 to $34.30 through 2026. The $25.68 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The DNLI price prediction for 2027 points to an average of $30.99 (low $24.94, high $40.56) — a potential gain of +21% on today's $25.68. Buyers look set to stay in control over this stretch.
In 2028, DNLI is projected to trade between $30.49 and $52.50, averaging $38.80 — a potential gain of +51% from today's $25.68. That is up +25% on the projected 2027 average. Momentum favours further upside here.
Denali Therapeutics Inc.'s 2029 outlook centres on $47.55, within a $36.62 to $66.03 range. That is up +23% on the projected 2028 average. That marks a +85% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, DNLI could reach as high as $80.57, with a base case around $56.77 and support toward $42.95 — roughly +121% from $25.68. Momentum favours further upside here.
Expect DNLI to range from $46.19 to $89.75 through 2031. The $62.04 average target implies a +142% move from current prices. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The DNLI price prediction for 2032 points to an average of $63.87 (low $46.85, high $94.00) — a potential gain of +149% on today's $25.68. Momentum favours further upside here.
In 2033, DNLI is projected to trade between $53.77 and $111.13, averaging $74.33 — a potential gain of +189% from today's $25.68. That is up +16% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Denali Therapeutics Inc.'s 2034 outlook centres on $80.85, within a $57.72 to $122.63 range. That is up +9% on the projected 2033 average. That marks a +215% change versus current levels. Momentum favours further upside here.
By 2035, DNLI could reach as high as $142.57, with a base case around $92.75 and support toward $65.38 — roughly +261% from $25.68. Buyers look set to stay in control over this stretch.
Expect DNLI to range from $90.59 to $221.19 through 2040. The $136.02 average target implies a +430% move from current prices. That is up +47% on the projected 2035 average. Momentum favours further upside here.
The DNLI price prediction for 2050 points to an average of $315.50 (low $190.81, high $557.23) — a potential gain of +11.3x on today's $25.68. Buyers look set to stay in control over this stretch.
Investing $1,000 in DNLI today (≈ 38.94081 DNLI) could be worth
$12,285.69
+$11,285.69 (+1129%) by 2050 · US Dollar
Based on the average projected DNLI price of $315.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DNLIwould be worth at today's price.
$1,000 invested in DNLI on Jul 10, 2025 (≈ 65.146578 DNLI) would be worth
$1,672.96
+$672.96 (+67.3%) today · 1.67× · US Dollar
Based on a DNLI entry price of $15.35 vs. today's $25.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $25.83 | $994.19 | -0.6% |
| 1 month ago | $20.61 | $1,246 | +24.6% |
| 3 months ago | $19.23 | $1,335.41 | +33.5% |
| 6 months ago | $17.95 | $1,430.64 | +43.1% |
| 1 year ago | $15.35 | $1,672.96 | +67.3% |
| All time (5.0y) ago | $69.53 | $369.34 | -63.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DNLI forecast.
Our base-case forecast reaches $51.00 around 2030.
Implied market cap at $51.00: $8.09B
The multi-year forecast portrays a strong bullish trajectory beyond the near term. The sequence shows 2026 as a neutral baseline, with 2027–2035 progressively higher, culminating in a 2030 average of $58.82 (ROI 130) and a 2040 average of $143.20 (ROI 460). The bullish pattern continues to 2050, where the average is $342.77 (ROI 1240.5).
Forecast sentiment throughout 2027–2050 is labeled BULLISH, reflecting expected upside in the annual average prices. These figures illustrate substantial upside potential over the coming years, tempered by the uncertainty inherent in long-horizon estimates. These are estimates, not guarantees, and actual results will depend on market conditions and other factors.
Tap a question to reveal the answer.
2030 min $43.90, avg $58.82, max $84.85; ROI 130.
Forecasts show a bullish path from 2027 onward, with 2027 avg $31.31, 2028 avg $39.54, 2029 avg $49.92, and 2030 avg $58.82; ROI climbs to 130 by 2030 and to 1240.5 by 2050, though these are estimates and not guarantees.
2035 min $68.42, avg $99.08, max $155.58; this indicates a path where the price could reach or exceed $100 in 2035 (based on the forecast’s max and average).
2050 min $199.46, avg $342.77, max $623.32; ROI 1240.5.
RSI14 is 70; SMA50 is $20.40 and SMA200 is $18.56. Support is $18.11 and resistance is $24.82. The 30-day range is $21.53–$30.37, with annualized volatility at 50%.
Denali Therapeutics Inc. Community Discussion
0Share your Denali Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.